Last updated: June 17, 2026
Ultragenyx Pharma v. Navinta 2:26-cv-03585: Litigation Summary, Claims, and Business Impact
Executive summary: The case Ultragenyx Pharmaceutical Inc. v. Navinta LLC, No. 2:26-cv-03585 (filed 2026) is a patent infringement dispute tied to generic or biosimilar-style market entry pressures. The docket number indicates a federal IP case in the District of New Jersey. A complete litigation summary (claims, asserted patents, procedures, and status) cannot be produced from the information provided.
What patents are asserted in Ultragenyx Pharma v. Navinta LLC 2:26-cv-03585?
A litigation summary depends on the asserted patent list contained in the complaint, initial disclosures, or early scheduling orders. With only the case caption and docket number provided, the asserted patents, assignees, and claim numbers are not determinable.
Which patent numbers are listed in the complaint
- Not available from the provided input.
Are the asserted patents Orange Book listed patents or other IP
- Not available from the provided input.
What is the procedural posture in 2:26-cv-03585 (filed, answered, Markman, injunction, discovery)?
A credible posture requires docket events and dates (e.g., Rule 16 scheduling order, motion to dismiss, answer, Markman order, claim construction hearing, preliminary injunction briefing, dispositive motions, and trial date).
- Not available from the provided input.
Is there a Paragraph IV filing or Hatch-Waxman-style theory
- Not available from the provided input.
Is this an ANDA, 505(b)(2), or biosimilar case
- Not available from the provided input.
What is being accused: infringement theory, product(s) at issue, and accused process claims?
An analysis requires the accused product description (or biosimilar designation), manufacturing route/process allegations, and the claim chart-level detail that appears in pleadings or expert reports.
- Not available from the provided input.
Method of use vs composition-of-matter vs formulation patents
- Not available from the provided input.
Do the claims focus on dosage form, stability, or delivery system
- Not available from the provided input.
How strong is Ultragenyx’s patent case in 2:26-cv-03585?
Patent strength analysis requires at least one of:
- asserted patent independent claim features,
- prosecution history and remaining claim scope,
- claim construction outcomes,
- infringement contentions and validity defenses,
- cited prior art and any PTAB activity.
No such substance is available from the provided input.
What prior art and invalidity grounds are invoked
- Not available from the provided input.
Is there a PTAB parallel: IPR, PGR, or CBM
- Not available from the provided input.
What invalidity defenses does Navinta LLC raise in the case?
Invalidity analysis requires the affirmative defenses and any motion practice (Rule 12/56), including:
-
anticipation/obviousness theories,
-
indefiniteness,
-
written description/enablement,
-
inequitable conduct (if pleaded),
-
jurisdictional or standing attacks.
-
Not available from the provided input.
Are there noninfringement counterarguments
- Not available from the provided input.
Are there design-around or “no equivalence” positions
- Not available from the provided input.
What happened in court so far: key orders, hearings, and filings
A litigation timeline must cite docket events (filing date, service, answer deadline, motions, orders). The input provides no docket entry list or dates.
- Not available from the provided input.
Early motions that commonly drive outcome
- Not available from the provided input.
Markman timeline and impact on claim scope
- Not available from the provided input.
Does the case involve an injunction or settlement pressure?
Injunction exposure depends on:
-
whether Ultragenyx sought preliminary injunctive relief,
-
likelihood-of-success factors,
-
irreparable harm allegations,
-
any settlement signals in court orders or consent judgments.
-
Not available from the provided input.
Has there been a consent order or stipulation of dismissal
- Not available from the provided input.
Is the case stayed pending PTAB
- Not available from the provided input.
What generic launch or market-entry risk exists for Navinta in 2:26-cv-03585?
Launch risk is tied to:
- expiration dates of asserted patents,
- exclusivity status (Orange Book, pediatric exclusivity, REMS/IPR outcomes),
- any stay agreements (Hatch-Waxman),
- timing of FDA approval and launch carve-outs.
No drug identity or patent dates are provided in the input.
- Not available from the provided input.
How does Ultragenyx’s broader enforcement strategy compare to prior Ultragenyx v. generic cases?
Strategy comparison requires a list of similar cases (other docket numbers, judges, courts, frequently asserted patents, and outcomes). That dataset is not present in the provided input.
- Not available from the provided input.
Key Takeaways
- No patent-assertion, procedural, or merits details are present in the provided input, so a complete litigation summary for Ultragenyx Pharmaceutical Inc. v. Navinta LLC, 2:26-cv-03585 cannot be produced in a way that is accurate and decision-grade.
- Business impact analysis (launch timing, injunction leverage, validity attack strength) also requires asserted patent numbers, FDA product/pathway context, and docket milestones, none of which are supplied.
FAQs
- What documents control the asserted patents in Ultragenyx v. Navinta (2:26-cv-03585)?
- Does 2:26-cv-03585 indicate a Hatch-Waxman Paragraph IV challenge or a different infringement posture?
- What is the typical schedule for Markman and dispositive motions in District of New Jersey IP cases?
- How do PTAB IPR outcomes typically affect district court infringement timelines and settlement leverage?
- What facts determine whether a preliminary injunction is likely in pharma patent disputes involving generics?
References
